The research group of Prof. Dominik Saul is part of the Robert Bosch Center for Tumor Diseases (RBCT). The RBCT is a newly founded non-profit translational cancer research institute at the Bosch Health Campus (BHC) in Stuttgart, in direct proximity to the Robert Bosch Hospital (RBK). As a part of the National Center for Tumor Diseases (NCT) Southwest and the Comprehensive Cancer Center Tübingen-Stuttgart, the RBCT is dedicated to innovative cancer research and the development of new treatment strategies. The Saul group has a particular interest and expertise in cellular senescence. In particular, we utilize state-of-the-art techniques such as various genome-/transcriptome-wide sequencing approaches, multiplex immunofluorescence staining of tissues as well as genetic engineering and other work on tumor cell lines. Our main research goal is to explore cellular senescence and the senescence-associated secretory phenotype (SASP) in cancer cells and the tumor microenvironment during tumor development, progression and metastasis. We aim to decipher underlying molecular mechanisms in order to identify novel therapeutic targets to improve treatment response. Group description: : https://www.rbct.de/en/cellular-senescence-cancer-and-bone-metastasis